Newsletter January 2021 No.201
Top News
The worldwide spread of novel coronavirus infection (COVID-19) is having a tremendous impact on global society and the economy. On June 17, 2020, the JPMA compiled and disseminated the "JPMA Proposal for the Creation of Therapeutic Agents and Vaccines for Infectious Diseases". The proposal is designed to overcome the challenges of preparing for future unknown infectious diseases, while promoting activities based on a strong awareness of our mission as an R&D-oriented pharmaceutical company, which is the early creation of treatments and vaccines and the stable supply of pharmaceutical products. The proposal emphasizes the importance of further collaboration between industry, academia, and government in order to strengthen measures against infectious diseases in Japan. As part of its efforts to realize the proposal, JPMA participated in the 7th Nikkei-FT Conference on Infectious Diseases (online conference format) and held a JPMA lunch session on November 7, the second day of the conference. In this session, key persons from industry, academia, and government presented information on how Japan should respond in the future for the rapid discovery and supply of drugs and vaccines for infectious diseases, preparedness in normal times, necessary functions, international collaboration, and other issues.
Topics
- The 8th Taiwan-Japan Pharmaceutical Conference to be held
- FY2020 Meeting of Code Administration Managers and Practitioners
- Joint Assembly of the Drug Evaluation Committee and Regulatory Affairs Committee for FY2020" was held.
- Report on the "BioJapan 2020" and Participation in the Biopharmaceutical Committee Seminar